22 May 2013
Keywords: azd0837, comparable, profile, vkas, ph, ii, study
Article | 30 March 2009
Data presented at the annual meeting of the American College of Cardiology in Florida, show that Anglo-Swedish drug major AstraZeneca's
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 March 2009
21 May 2013
© 2013 thepharmaletter.com